The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
Abstract
Purpose: Brivanib is a selective dual inhibitor of vascular endothelial growth factor and fibroblast growth factor receptors implicated in tumorigenesis and angiogenesis in hepatocellular carcinoma (HCC). An unmet medical need persists for patients with HCC whose tumors do not respond to sorafenib or who cannot tolerate it. This multicenter, double-blind, randomized, placebo-controlled trial assessed brivanib in patients with HCC who had been treated with sorafenib. Patients and Methods: In all, 395 patients with advanced HCC who progressed on/after or were intolerant to sorafenib were randomly assigned (2:1) to receive brivanib 800 mg orally once per day plus best supportive care (BSC) or placebo plus BSC. The primary end point was overall survival (OS). Secondary end points included time to progression (TTP), objective response rate (ORR), and disease control rate based on modified Response Evaluation Criteria in Solid Tumors (mRECIST) and safety. Results: Median OS was 9.4 months for brivanib and 8.2 months for placebo (hazard ratio [HR], 0.89; 95.8% CI, 0.69 to 1.15; P = .3307). Adjusting treatment effect for baseline prognostic factors yielded an OS HR of 0.81 (95% CI, 0.63 to 1.04; P = .1044). Exploratory analyses showed a median time to progression of 4.2 months for brivanib and 2.7 months for placebo (HR, 0.56; 95% CI, 0.42 to 0.76; P < .001), and an mRECIST ORR of 10% for brivanib and 2% for placebo (odds ratio, 5.72). Study discontinuation due to treatment-related adverse events (AEs) occurred in 61 brivanib patients (23%) and nine placebo patients (7%). The most frequent treatment-related grade 3 to 4 AEs for brivanib included hypertension (17%), fatigue (13%), hyponatremia (11%), and decreased appetite (10%). Conclusion: In patients with HCC who had been treated with sorafenib, brivanib did not significantly improve OS. The observed benefit in the secondary outcomes of TTP and ORR warrants further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationEASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Self-citationCheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Self-citationSorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Lencioni, R., & Llovet, J. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1247132 · Cited by 4,329
Self-citationForner, A., Llovet, J. M., & Bruix, J. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61347-0 · Cited by 4,022
Self-citationModes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
Llovet, J. M., Di Bisceglie, A. M., Bruix, J., Kramer, B. S., Lencioni, R., Zhu, A. X., Sherman, M., Schwartz, M., Lotze, M., Talwalkar, J., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn134 · Cited by 1,653
Self-citationCasanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621
Llovet, J. M., Ducreux, M. P., Lencioni, R. A., Bisceglie, A. M. D., Dufour, J., Greten, T. F., Raymond, É., Roskams, T., Mazzaferro, V., Bruix, J., et al. (2012) · Cited by 1,488
Self-citationFibroblast growth factor/fibroblast growth factor receptor system in angiogenesis
Presta, M., Dell’Era, P., Mitola, S., Moroni, E., Ronca, R., & Rusnati, M. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.004 · Cited by 1,261
Johnson, P. J., Qin, S., Park, J.-W., Poon, R. T. P., Raoul, J.-L., Philip, P. A., Hsu, C.-H., Hu, T.-H., Heo, J., Xu, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4410 · Cited by 772
Self-citationSantoro, A., Rimassa, L., Borbath, I., Daniele, B., Salvagni, S., Van Laethem, J. L., Van Vlierberghe, H., Trojan, J., Kolligs, F. T., Weiss, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70490-4 · Cited by 554
Self-citationFibroblast growth factor signaling in tumorigenesis
Grose, R., & Dickson, C. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.003 · Cited by 404
Management of hypertension in angiogenesis inhibitor-treated patients
Izzedine, H., Ederhy, S., Goldwasser, F., Soria, J. C., Milano, G., Cohen, A., Khayat, D., & Spano, J. P. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn713 · Cited by 347
VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management
Izzedine, H., Massard, C., Spano, J. P., Goldwasser, F., Khayat, D., & Soria, J. C. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2009.11.001 · Cited by 332
Mise, M., Arii, S., Higashituji, H., Furutani, M., Niwano, M., Harada, T., Ishigami, S., Toda, Y., Nakayama, H., Fukumoto, M., et al. (1996) · Hepatology · doi:10.1002/hep.510230309 · Cited by 307
Edeline, J., Boucher, E., Rolland, Y., Vauléon, E., Pracht, M., Perrin, C., Le Roux, C., & Raoul, J. (2012) · Cancer · doi:10.1002/cncr.26255 · Cited by 275
Self-citationHuynh, H., Ngo, V. C., Fargnoli, J., Ayers, M., Soo, K. C., Koong, H. N., Thng, C. H., Ong, H. S., Chung, A., Chow, P., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0509 · Cited by 221
Finn, R. S., Kang, Y.-K., Mulcahy, M., Polite, B. N., Lim, H. Y., Walters, I., Baudelet, C., Manekas, D., & Park, J.-W. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1991 · Cited by 215
Self-citationEl-Assal, O. N., Yamanoi, A., Ono, T., Kohno, H., & Nagasue, N. (2001) · PubMed · Cited by 195
Allen, E., Walters, I. B., & Hanahan, D. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2847 · Cited by 157
Self-citationPark, J., Finn, R. S., Kim, J. S., Karwal, M., Li, R. K., Ismail, F., Thomas, M. B., Harris, R., Baudelet, C., Walters, I. B., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2011 · Cited by 148
Self-citationCai, Z., Zhang, Y., Borzilleri, R. M., Qian, L., Barbosa, S. A. L., Wei, D. D., Zheng, X., Wu, L., Fan, J., Shi, Z., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7013309 · Cited by 144
Poon, R. T., Ng, I. O., Lau, C. P.-Y., et al. (2001) · The American Journal of Surgery · doi:10.1016/s0002-9610(01)00708-5 · Cited by 131
Self-citationSecond-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to Sorafenib
Villanueva, A., & Llovet, J. M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0151 · Cited by 105
Self-citationHypertension and proteinuria: a class-effect of antiangiogenic therapies
Launay‐Vacher, V., & Deray, G. (2008) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3283161012 · Cited by 103
Ogasawara, S., Yano, H., Iemura, A., et al. (1996) · Hepatology · doi:10.1002/hep.510240132 · Cited by 81
Bhide, R. S., Lombardo, L. J., Hunt, J. T., Cai, Z., Barrish, J. C., Galbraith, S. M., Jeyaseelan, R., Mortillo, S., Wautlet, B. S., Krishnan, B. S., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0472 · Cited by 73
Uematsu, S., Higashi, T., Nouso, K., Kariyama, K., Nakamura, S., Suzuki, M., Nakatsukasa, H., Kobayashi, Y., Hanafusa, T., Tsuji, T., et al. (2005) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2005.03726.x · Cited by 67
Flushing Oral Oncology Drugs Down the Toilet
Ratain, M. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.1617 · Cited by 55
Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: A cohort study
Feldt, S., Schüssel, K., Quinzler, R., Franzmann, A., Czeche, S., Ludwig, W.-D., & Schulz, M. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.01.036 · Cited by 47
Garrett, C. R., Siu, L. L., El-Khoueiry, A. B., Buter, J., Rocha‐Lima, C., Marshall, J. L., LoRusso, P. M., Major, P. P., Chemidlin, J., Mokliatchouk, O., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.182 · Cited by 31
Ratain, M. J., Schwartz, G. K., Oza, A. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3079 · Cited by 24
Schwartz, G. K., Maki, R. G., Ratain, M. J., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.10000 · Cited by 21
Cited by
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationEASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Self-citationA New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Self-citationForner, A., Reig, M., & Bruix, J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30010-2 · Cited by 5,531
Self-citationVillanueva, A. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1713263 · Cited by 4,508
Metadata
- Authors
- Llovet, J. M., Decaens, T., Raoul, J.-L., Boucher, E., Kudo, M., Chang, C., Kang, Y.-K., Assenat, E., Lim, H.-Y., Boige, V., Mathurin, P., Fartoux, L., Lin, D.-Y., Bruix, J., Poon, R. T., Sherman, M., Blanc, J.-F., Finn, R. S., Tak, W.-Y., Chao, Y., Ezzeddine, R., Liu, D., Walters, I., & Park, J.-W.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-10-01
- Volume
- 31
- Issue
- 28
- Pages
- 3509-3516
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2051684210
- Cited by
- 596
- References
- 38
- FWCI
- 37.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.